|Description||Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).|
|Solubility||Soluble in DMSO|
|Storage||Store at -20 °C|
|Application||A peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist.|
|Quality Standard||Enterprise standard|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.|
|Melting Point||123-125 °C|
|Current Developer||Bristol-Myers Squibb|
In vitro, the IC50 for growth inhibition is approximately 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three- to fourfold in nude ...
BMS-687453 is a potent and selective peroxisome proliferator activated receptor PPARα agonist. with an IC50 of 10 nM for human PPARalpha and approximately 410-f...
FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist.
GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CC...
Naveglitazar is a Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist
PPAR agonist 1
An agonist of PPAR α and PPAR γ
Troglitazone, PPARγ agonist, is an anti-diabetic thiazolidinedione (TZD) with anti-inflammatory and anti-tumor activity, which was approved for the treatment of...
SR 1664 is a PPARγ (peroxisome proliferator-activated receptor γ ) inhibitor. SR 1664 can block PPARγ by cyclin-dependent kinase 5 with an IC50 value of 80 nM a...
LY518674, a phenoxypropionic acid derivative, is a Potent and selective PPAR-alpha agonist produced a dose-dependent increase in serum HDL-c, resulting in 208 +...
MCC-555, a thiazolidinedion derivative, has been found to be a PPAR agonist that was once studied as hyperglycaemic and hyperlipidaemic. The Phase II trial agai...
Pioglitazone HCl is a hydrochloride salt form of pioglitazone which is a cytochrome P450 (CYP)2C8 and CYP3A4 enzymes inhibitor for CYP2C8, CYP3A4 and CYP2C9 wit...
Saroglitazar magnesium is a dual PPAR agonist with potent predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, res...
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
INT 131 is a hypoglycemic agent, displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared...
PT-S58 is a full peroxisome proliferator-activated receptor (PPAR) β/δ antagonist as a derivative of GSK0660. But PT-S58 has a three-fold higher affinity for th...
JW74 is a tankyrase-specific inhibitor. JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. At the molec...
GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties.
Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.
Seladelpar is a selective peroxisome proliferator-activated receptor -δ receptor agonist. Phase II clinical trials for the treatment of Hyperlipidaemia, Hyperli...
Imiglitazar, also known as TAK-559，with hypoglycemic activity it is a non-thiazolidinedione dual peroxisome proliferator-activated receptor (PPAR) alpha and gam...